A Phase 1, Non-Randomized, Open-Label Trial to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2018
At a glance
- Drugs TD 8954 (Primary)
- Indications Gastrointestinal motility disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 13 Sep 2018 Status changed from recruiting to completed.
- 02 Jul 2018 Planned End Date changed from 28 Jun 2018 to 10 Aug 2018.
- 02 Jul 2018 Planned primary completion date changed from 28 Jun 2018 to 31 Jul 2018.